AllSci News
Celea raises USD 180m to launch first head-to-head superiority trial in IPF
Boston-based Celea Therapeutics announced the completion of a USD 180 million private placement to fund initiation of a pivotal Phase III trial in...
Otsuka's Voyxact becomes first APRIL inhibitor to stabilize kidney function in IgAN over two years
Otsuka's sibeprenlimab (Voyxact) has delivered statistically significant eGFR stabilization with evidence of improvement over two years in the full dataset...
EC approves Novartis’s Itvisma as first gene therapy for older SMA patients
The European Commission has approved Itvisma (onasemnogene abeparvovec) for the treatment of children aged two years and older, teenagers, and adults with…
BridgeBio secures USD 1b to scale Attruby launch and fund three incoming programs
Palo Alto-based BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced a USD 1 billion private placement of Series A Cumulative Convertible Participating Preferred...
AlzeCure licenses first-in-class Alzheimer's drug to QuantumCell for USD 2.2b
Sweden-based AlzeCure Pharma AB (STO: ALZCUR) has out-licensed global rights to its NeuroRestore platform and lead ACD856 drug candidate to Denmark-based...
Roche's divarasib beats approved KRAS G12C rivals in landmark head-to-head Phase III trial
Roche (SIX: RO; OTCQX: RHHBY) has reported that divarasib, its investigational next-generation KRAS G12C inhibitor, demonstrated statistically significant...
European Investment Bank backs Orano's lead-212 isotope supply chain with EUR 125m facility loan
France's Orano secures EIB development loan to fund lead-212 cancer therapy infrastructure, with the EU's backing reflecting both the clinical and...
FDA grants Intent Bio BTD for PEP biologic in diabetic foot ulcers
Minnesota-based INTENT Biologics announced receipt of US FDA Breakthrough Therapy Designation (BTD) for PEP Biologic (Purified Exosome Product), a platelet-derived exosome biologic,…
Neurogene raises USD 125m to accelerate Rett syndrome gene therapy toward approval
New York-based Neurogene Inc. (Nasdaq: NGNE) announced the pricing of a USD 125 million public offering of common stock and pre-funded warrants on July 1,...
Alvotech secures USD 75m term loan to fund FDA resubmissions and global launches
Iceland-based Alvotech (Nasdaq: ALVO) announced a USD 75 million term loan facility on July 1, 2026, adding non-dilutive debt capital to fund R&D pipeline...
Lonza reshapes CDMO model with proprietary CNS delivery platform acquisition from Nona
Lonza has struck a deal to acquire IP rights to Nona Biosciences' single-domain antibody BBB-crossing technology, marking an unusual move by the Swiss CDMO...
Vertex expands label for Casgevy to young children with sickle cell disease
The US FDA has supplementally approved Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with sickle cell disease (SCD) with…
Abbisko to pair oral PD-L1 inhibitor with AstraZeneca's Tagrisso in combination trial for NSCLC
Shanghai-based Abbisko Therapeutics (HKEX: 02256.HK) has entered a clinical collaboration with AstraZeneca (NYSE: AZN) to evaluate lumipodlin (ABSK043), a...
Takeda bets USD 600 million on Insilico's generative AI platform for drug discovery
Takeda has struck a deal worth up to USD 600 million with Insilico Medicine (HKEX: 3696), gaining access to the company's Pharma.AI generative AI platform...
Abivax raises USD 800m in upsized offering to fund obefazimod US commercialization push
France-based Abivax SA (Euronext Paris / Nasdaq: ABVX) announced the pricing of an upsized underwritten public offering of American Depositary Shares,...
The AllSci Brief
Systematic R&D and deal news. Daily.